Rho kinase
inhibitor, also
known as ROCK inhibitor, inhibits the rho kinases, a family of small GTP-binding
protein. Rho kinases are found to regulate cell motility, proliferation, shape,
gene expression, apoptosis, and are also involved in the signalling pathway.
The inhibition of rho kinases has shown some beneficial effects in
cardiovascular diseases, including systemic hypertension, vasospastic angina,
stable effort stigma, pulmonary hypertension, stroke, and heart failure.
Rho kinases
are a member of serine/threonine kinases and are encoded by ROCK1 and ROCK2
gene. There are many evidences that show rho kinase inhibitors play a
significant role in improving symptoms related to cardiovascular diseases, as
it has been experimentally proven that rho kinase gets upregulated in the
cardiovascular disorders. The development of inhibitors of rho kinase isoforms can
be an advantage, inclined to the specificity of the cardiovascular disorders.
In addition, the pathophysiology of other disorders, such as intracerebral
hemorrhage, diabetes, Parkinson’s disease, and Alzheimer’s disease are related
to the modulation of rho kinases.
Request
to Get the Sample Pages at:
The report
provides a comprehensive understanding of the pipeline activities covering all
drug candidates under various stages of development, with the detailed analysis
of pipeline and clinical trials. Pipeline analysis of drugs by phases includes
product description and development activities including information about
clinical results, designations, collaborations, licensing, grants, technology,
and others.
No comments:
Post a Comment